MD-3 (University of London)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameMD-3 (University of London)
Drug Alias NameMD-3 (BMS)type I signal peptidase inhibitors (Bristol-Myers Squibb/Infectious Disease Research Institute/Queen Mary University of London)MD-4
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of Actiontype I signal peptidase inhibitors
Targetstype I signal peptidase
Therapy Area/IndicationsBacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesQueen Mary University Of London
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAccess to Advanced Health InstituteQueen Mary University Of LondonBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsBacterial Infections

Other Information

ATC CodeN/A
Related LinksN/A